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INTRODUCTION
Veno-occlusive disease of the liver (VOD), a common,
potentially serious complication of high-dose cytoreductive
therapy, is a clinical syndrome characterized by hyperbiliru-
binemia, hepatomegaly, and sudden weight gain caused by
fluid accumulation [1,2]. Histologic correlates of the clinical
syndrome include hepatocyte necrosis and sinusoidal fibro-
sis in zone 3 of the liver acinus, micro t h romboses in the
walls and sinusoidal pores of the terminal hepatic venules,
and deposition of extracellular matrix in sinusoids and
venules [3,4]. The clinical course of VOD is usually self-
limited, but in some series the case fatality rate is as high as
28% [1,2].
The regimens of cytoreductive therapy used to prepare
patients for hematopoietic cell transplantation vary in their
p ropensity to cause severe or fatal VOD. One import a n t
variable is the dose intensity. For example, higher doses of
busulfan in adults receiving bufulfan/cyclophosphamide reg-
imens, and higher doses of irradiation in cyclophos-
phamide/total-body irradiation (TBI) regimens, have been
shown to lead to more severe VOD [1,5–7]. Another vari-
able is the choice of chemotherapy agents. Some drugs are
more toxic to the cells in zone 3 of the liver acinus than oth-
ers, probably because their activation and conjugation
within hepatocytes differs [8–10]. As a class, alkylating
agents have a low incidence of liver toxicity when used as
single agents. This experience, however, must be interpreted
c a u t i o u s l y, since patients receiving these agents have not
often received maximally tolerated doses. The dose-limiting
factor for alkylating agents, myelosuppression, has been
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ABSTRACT
The purpose of this study was to determine the incidence of veno-occlusive disease (VOD) after a high-dose re g i-
men of busulfan, melphalan, and thiotepa and the risk factors for a more severe outcome. We followed 253 consecu-
tive patients with malignant disorders who received autologous transplants after stem cell harvest followed by 12 m g / k g
busulfan, 100 mg/m2 melphalan, and 500 mg/m2 thiotepa. Diagnosis of VOD was based on weight gain,
h e p a t o m e g a l y, and jaundice. Risk factors for moderate or severe VOD were identified using logistic re g re s s i o n
models. VOD occurred in 70 of 253 patients (28%), of whom 31 (12%) had moderate and 11 (4%) severe VOD. The
median day of onset of hyperbilirubinemia was day 9, significantly later than the onset of jaundice after our
cyclophosphamide-based regimens (p , 0.001). Resolution of weight gain and jaundice, followed by their re a p p e a r-
ance several weeks later, occurred in 23 of 70 patients with VOD and was an adverse prognostic sign. Risk factors
for moderate or severe VOD were a diagnosis of lymphoma or myeloma (odds ratio [OR] 2.65 compared with bre a s t
cancer), tumor involvement in the liver (OR 3.95), fever in the month before transplant (OR 3.32), and prior radia-
tion therapy (OR 2.70). We conclude that VOD after busulfan, melphalan, and thiotepa was less frequent and less
s e v e re and developed later than VOD after our historical cyclophosphamide-based regimens. Significant risk factors
included a diagnosis other than breast cancer, hepatic metastases, persistent fever, and prior radiation therapy. This
study suggests that alkylating agents of comparable overall toxicity differ in their liver toxicity.
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o v e rcome by hematopoietic cell grafting, making possible
significantly higher doses and combinations of alkylating
agents [11–22]. The use of multidrug regimens that contain
alkylating agents appears to lead to a higher frequency and
severity of VOD than single-agent use, but attribution of
VOD to specific alkylating agents is problematic. 
We studied 253 consecutive patients with malignant dis-
o rders who received autologous hematopoietic cell trans-
plants after a conditioning regimen of three alkylating
agents (busulfan, melphalan, and thiotepa [BuMelTT])
given in high doses [23,24]. We sought to determine the
incidence and severity of VOD after this regimen. We were
also interested in what might predispose patients to develop
more severe VOD. In general, most candidates for autolo-
gous transplantation for solid tumors lack pretransplant risk
factors for severe VOD such as hepatitis C, herpesviru s
infections, and persistent fever, compared with patients with
hematologic malignancies [1,25,26]. We had also noted that
the onset of VOD after BuMelTT conditioning therapy was
delayed in some patients compared with the onset of VOD
after cyclophosphamide-based conditioning regimens, sug-
gesting that the initial toxic injury from BuMelTT within
the liver was followed by secondary events that caused later
obstruction of liver blood flow. We compared the onset and
the progression of VOD after BuMelTT to that following
busulfan/cyclophosphamide and cyclophosphamide/TBI [1]
to examine this possibility. 
MATERIALS AND METHODS
Patient selection
We evaluated 253 consecutive patients who re c e i v e d
BuMelTT as conditioning therapy for autologous hemato-
poietic stem cell transplants, under protocols from the the
F red Hutchinson Cancer Research Center, between April
1993 and February 1996. 
Stem cell mobilization and harv e s t
Mobilization regimens pre p a r a t o ry to collection of
peripheral blood stem cells were given to 245 patients
(Table 1), as previously published [23,24]. For mobilization
using granulocyte colony-stimulating factor (G-CSF),
leukapheresis was started from day 4 of G-CSF administra-
tion for 3 consecutive days. For mobilization using chemo-
therapy, G-CSF was started on day 4 at a dose of 10 mg/kg
per day until leukapheresis was completed. Leukaphere s i s
was initiated when the white blood cell (WBC) count was
.1 0 0 0 / m m3 f rom the nadir and continued until .531 06
C D 3 4+ cells had been collected. Leukapheresis was per-
f o rmed with the use of automated continuous-flow blood
cell separators (Spectra, Code Laboratories, Engelwood,
CO; CS-3000, Fenwal, Round Lake, IL). 
Administration of chemotherapeutic agents and
transplant techniques
Busulfan was given orally at 1 mg/kg every 6 hours on
days –8, –7, and –6 for a cumulative dose of 12 mg/kg, 50
mg/m2 intravenous melphalan per day on days –5 and –4 for
a cumulative dose of 100 mg/m2, and intravenous thiotepa
on days –3 and –2 for a cummulative dose of 350–550
mg/m2 [23,24]. For 30 patients who were thought by their
attending physicians to be at increased risk for re g i m e n -
related toxicity, eight blood samples were collected after the
first dose of busulfan and analyzed for plasma busulfan con-
centration using gas chromatography and mass selective
detection. Dose adjustments were made on the third dose if
the steady-state concentration was outside the target range
of 400–900 ng/mL. Busulfan measurements were also made
after the fifth and ninth doses, with similar dose adjust-
ments. The day of peripheral blood stem cell or marro w
infusion was day 0, and all posttransplant events were dated
from that day. 
Definition of VOD and its sev e r i t y
A diagnosis of VOD was made when at least two of the
following events developed within 50 days of transplanta-
tion: sudden weight gain (.2% of baseline body weight,
defined as the weight preceding the first dose of busulfan),
h y p e r b i l i rubinemia (total serum bilirubin .2 mg/dL), and
Table 1. Demographics of the patient population (n5253)
No. of patients (%) 
Diagnosis
Breast cancer 123 (49)
Non Hodgkin’s lymphoma 42 (17)
Ovarian cancer 21 (8)
Hodgkin’s disease 20 (7)
Myeloma* 14 (6)
Sarcoma 13 (5)
Primary neuroectodermal tumor 9 (4)
Other solid tumors† 11 (4)
Source of hematopoietic stem cells
Autologous peripheral blood stem cells 234 (93)
Syngeneic donor peripheral blood stem cells 5 (2)
Autologous marrow 6 (2)
Autologous marrow and 
peripheral blood stem cells 8 (3)
Thiotepa dose‡
350 mg/m 2 2 (1)
450 mg/m 2 6 (2)
500 mg/m 2 242 (96)
550 mg/m 2 3 (1)
Stem cell harvest regimen
Cyclophosphamide 1 etoposide 95 (38)
Taxol-containing 67 (26)
G-CSF 53 (21)
Adriamycin-containing 8 (3)
Ifosphamide-containing 8 (3)
Other regimens 15 (6)
No stem cell harvest regimen§ 7 (3)
Sex
Male 68 (27)
Female 185 (73)
*Includes two patients with a diagnosis of myeloma and myelodysplastic sny-
drome.
†Testicular cancer (3), medulloblastoma (3), seminoma (2), germ cell tumor
(1), anal carcinoma (1), yolk sac tumor (1).
‡Thiotepa at the indicated doses was given in addition to busulfan (12 mg/kg)
and melphalan (100 mg/m2).
§Seven patients did not receive a stem cell harvest regimen: five were recipi-
ents of stem cells from syngeneic donors and two received autologous marrow.
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hepatomegaly or right upper quadrant pain of liver origin
[1]. The signs and symptoms must have developed in the
absence of other explanations. Patients were classified as
having “liver disease of uncertain etiology” if liver disease
developed that could be explained by sepsis syndrome, cardiac
failure, fungal liver infection, tumor infiltration, or the like.
Patients with both mild hyperbilirubinemia (total seru m
b i l i rubin ,2 mg/dL) and weight gain below the thre s h o l d
criterion of 2% were also classified in this category. Patients
w e re classified as having no VOD if there were no liver
abnormalities observed before day 50.
VOD was scored as mild, moderate, or severe by previ-
ously published criteria [1]. Patients classified as having mild
VOD had transient jaundice and weight gain that caused no
apparent adverse effects and were not treated. Patients clas-
sified as having moderate VOD had fluid retention requir-
ing diuretics or liver pain requiring analgesics, but signs and
symptoms of VOD were completely reversible by day 100
posttransplantation; that is, total serum bilirubin returned to
,2 mg/dL and weight returned to baseline. Patients classi-
fied as having severe VOD had jaundice and fluid retention
that was not reversible before death or day 100 posttrans-
plantation. Death was not a requirement for assignment to
the severe VOD category. 
Definition of organ failure
We defined the day of onset and severity of organ failure
using the following criteria. 1) Renal insufficiency: doubling
of the baseline creatinine level (the lowest serum creatinine
level 1–3 days before day 0); renal failure: creatinine level
$3 mg/dL. 2) Cardiac failure: radiographic evidence of an
increased cardiac size or the development of pulmonary vas-
cular congestion. 3) Pleural effusions: radiographic evidence
of fluid in the pleural space. 4) Pulmonary infiltrates: radi-
ographic evidence of diffuse interstitial infiltrates. 5) Need
for oxygen support, based on hypoxemia (oxygen saturation
,90%) by pulse oximetry. 6) Respiratory failure: need for
mechanical ventilation to sustain life. 7) Confusion or dis-
orientation: alterations in mental status. 8) Bleeding requir-
ing transfusion support: decrease in hematocrit caused by
blood loss, requiring red blood cell support. 
Risk factors for moderate to sev e re VO D
We collected demographic information, illness-re l a t e d
data from the time of diagnosis of malignancy, and detailed
i n f o rmation about the stem cell harvest regimen, medical
complications in the month preceeding transplantation, and
transplant pro c e d u re. Illness-related data included diagno-
sis, re l a p s e / remission status, number of cycles of chemo-
therapy before the stem cell harvest regimen, prior radiation
therapy given for problematic tumor (not part of a primary
t reatment regimen), and all of the relevant time interv a l s
(diagnosis to harvest, diagnosis to transplant, harvest to
transplant). For patients receiving a stem cell mobilization
regimen, we noted the individual drugs used and their doses,
as well as various categories of mobilization re g i m e n s
( Table 1). In the month before the start of the the
BuMelTT regimen, we noted the medication history, any
change in weight, re l a p s e / remission status, whether there
was tumor involvement of the liver on an imaging test,
o c c u rrence of febrile illness, and liver test results (seru m
b i l i rubin, aspartate transaminase [AST], alkaline phos-
phatase, and albumin) just before the conditioning regimen.
Details about the transplant procedure included the dose of
thiotepa (busulfan and melphalan doses were identical for all
patients) and the type of donor cells.
Statistical methods
Risk factors for moderate or severe VOD were identi-
fied using logistic regression. Multivariate regression models
w e re fit by including only variables that were signific a n t l y
associated with the probability of moderate or severe VOD.
Patients classified as having liver disease of unknown etiology
were not included in the analysis of risk factors. All reported
p values are two-sided, and those from regression models are
derived from the Wald test. No adjustments were made for
multiple comparisons. For this reason, we consider p values
in the range of 0.01 to 0.05 to be only suggestive and not
convincing evidence of a true association.
Using the Wilcoxon rank-sum test, the timing of the
clinical signs and symptoms of VOD among patients re c e i v-
ing BuMelTT was compared with a previously published
c o h o rt of patients with VOD that developed after re g i m e n s
containing busulfan/cyclophosphamide and cyclophos-
phamide/TBI [1]. The pro p o rtion of patients having a par-
ticular type of organ failure was compared among patients
with and without VOD using the x2 test or Fisher’s exact test
if assumptions necessary for asymptotic tests were not met.
RESULTS
Patient demo g r ap h i c s
Diagnoses, source of stem cells, stem cell harvest regi-
mens, and the conditioning regimen doses are given in
Table 1. The average age of the patients was 43.6 6 1 3 . 1
years (range 3.5–66). The majority of patients were women
with breast cancer.
I n c i d e n c e , sev e r i t y , and clinical course of V O D
Of the 253 patients, 70 patients met our criteria for
VOD (incidence of 28%). Of those 70 patients, 28 had mild
disease, 31 had moderate disease, and 11 had severe disease
(11, 12, and 4% of 253 patients). One hundred fifty patients
(59%) were classified as having no VOD (Table 2). 
Onset of VOD. In the current series, the mean day of
onset of hyperbilirubinemia was day 15.4 6 11.0 (median
day 9) (Table 2), significantly later than the mean day of
onset of jaundice in the previous experience (day 5.9 6 4.8)
(p , 0.001) [1]. The mean day of onset of sudden weight
gain .2% over baseline was day 4.4 6 12.6 (median day 3)
(Table 2) and was later than the day of onset of weight gain
in our previously published study of 190 patients with VOD
following cyclophosphamide-based conditioning re g i m e n s ,
in which the mean day of onset of weight gain was day 0.7 6
4.3. The diff e rence was not statistically significant. One
clinical consequence of this apparently later onset of VOD
than in our previous experience is that some patients had the
onset of disease at home, after engraftment and discharg e
from hospital. For example, 13 of 70 patients had onset of
weight gain after day 9 (mean day of onset in previous expe-
rience plus two standard deviations), and 23 of 70 had onset
of hyperbilirubinemia after day 15 (mean day of jaundice in
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p revious experience plus two standard deviations) [1]. The
later onset of VOD did not carry prognostic importance, as
the frequency of severe VOD among patients with a later
onset of weight gain (23%) or hyperbilirubinemia (17%)
was not significantly diff e rent from that among patients
whose onset of disease was earlier (14 and 15%, re s p e c-
tively) (p . 0.4 for both comparisons).
Double peaks of weight gain and hyperbilirubinemia. In this
c o h o rt of patients with VOD, we noted a phenomenon not
seen after other regimens of high-dose cytoreductive ther-
apy: onset of VOD (weight gain and jaundice), followed by
complete resolution of these features, followed by their re a p-
pearance several weeks later. Overall, 23 of 70 patients with
VOD exhibited this pattern of presentation. There appeare d
to be a relationship between this pattern and prognosis, since
it was seen in five of 28 patients (18%) with mild VOD, 11 of
31 (35%) with moderate VOD , and seven of 11 (64%) with
s e v e re VOD. The frequency of this pattern among patients
with severe VOD was significantly greater than among
patients with mild or moderate VOD (64 vs. 27%, p = 0.03).
For patients exhibiting this pattern, the average day of onset
of weight gain was day 0.9 6 7.3 (median day 2, range day –8
to 11) for the first peak and day 26.4 6 7.6 (median day 27,
range day 14–37) for the second peak. The onset of hyper-
b i l i rubinemia was on day 8.1 6 3.5 (median day 7, range day
4–17) for the first peak and day 26 6 6.6 (median day 27,
range day 15–36) for the second peak. 
Incidence and clinical course of patients with liv e r
disease of uncertain etiology
Liver disease of uncertain etiology was the classification
for 33 patients (13%). Of those patients, 18 had cholangitis
lenta related to septicemia [27]; 13 had isolated, minor ele-
vations of either body weight or bilirubin; one had cardiac
f a i l u re; and one developed hepatic graft-vs.-host disease.
Among patients classified as having liver disease of uncertain
etiology, the day-100 mortality was 21.2%; all patients who
died had sepsis syndrome and multiorgan failure. The mor-
tality rate was nil among patients who demonstrated isolated
elevations of either bilirubin or weight gain posttransplant
(Table 3).
D evelopment of organ failure
The frequency of organ damage to the kidneys, heart ,
and lungs and the development of confusion and bleeding
w e re all significantly more common among patients who
developed VOD than patients without VOD (data not
shown). In general, the frequency of organ failure was higher
among patients with severe VOD than among those with
moderate or mild VOD. From day 11 through 25 posttrans-
plant, patients with moderate or severe VOD were signifi-
cantly more likely to be febrile (OR 3.6), have sepsis syn-
d rome (OR 6.8), have positive blood cultures (OR 2.2), and
re q u i re intravenous vancomycin for unresponsive fever (OR
2.6) compared with patients with no VOD or mild VOD
(data not shown). From the data, we cannot determ i n e
whether these signs of infection were a result of damage to
the liver or a cause of multiorgan failure or both. It is of inter-
est that oral mucositis occurred in all patients, but the severity
of mucositis had no relationship to the severity of VOD.
M o r tality in patients with and without V O D
The overall day-100 mortality was 22 of 253 (8.7%).
The day-100 case fatality rate, according to the classification
of liver disease posttransplant, was 18.6% for all patients
with VOD, most of the deaths being accounted for by
patients with moderate or severe VOD (Table 3). Five
patients with severe VOD were treated with thro m b o l y t i c
therapy (intravenous tissue plasminogen activator [TPA] and
heparin); none responded. If there were no signs or symp-
toms of VOD posttransplant, day-100 mortality was 1.3%
(one patient died from aspiration pneumonia on day 6 and
one from postlaparotomy complications on day 90). 
Risk factors for moderate and sev e re VOD 
Univariate analysis. Radiation therapy delivered to the
thoracoabdominal ports before transplant was a risk factor for
moderate or severe VOD. Use of estro g e n - p rogestin therapy
b e f o re transplant, the nature of the PBSC harvest re g i m e n ,
and weight loss from harvest to transplant were marg i n a l l y
related to moderate or severe VOD. In contrast with pre v i o u s
studies, the pretransplant serum AST level was not pre d i c t i v e
of more severe VOD, but there was a relationship to a febrile
Table 2. Clinical presentation in 70 patients with VOD
All VOD cases Mild VOD Moderate VOD Severe VOD
n 70 28 31 11
Weight gain
No. of patients with .2% weight gain 64 25 28 11
Day of onset of weight gain 3 (–8 to 45) –4 (–8 to 32) 6 (–8 to 45) 3 (–7 to 26) 
Maximum weight gain posttransplant (% change from baseline) 6.2 (–1.3 to 36.5) 5.2 (–1.3 to 13.4) 10.1 (–2.1 to 36.5) 13.2 (8.7 to 25.9)
Day of maximum weight gain 32 (15 to 93) 29 (21 to 70) 32 (21 to 93) 38 (15 to 56)
Hepatomegaly
Number of patients with hepatomegaly 40 12 20 8
Day of onset of hepatomegaly 26 (–1 to 41) 23 (–1 to 41) 27 (3 to 38) 26 (7 to 33) 
Bilirubin
Number of patients with hyperbilirubinemia 61 25 25 11
Day of onset of hyperbilirubinemia 9 (4 to 47) 9 (5 to 36) 14 (5 to 47) 7 (4 to 27)
Maximum bilirubin posttransplant (mg/dL) 2.9 (0.6 to 47.9) 2.5 (0.6 to 7.5) 2.9 (0.6 to 10.1) 27 (9 to 47.9)
Day of maximum bilirubin 21 (4 to 59) 9 (4 to 40) 27 (7 to 49) 42 (16 to 59) 
Data are expressed as median (range).
310
episode in the month before the start of conditioning therapy,
as noted previously [1]. The underlying diagnosis had an
impact on severity of VOD, since patients with breast cancer
and other solid tumors had a lower frequency of moderate or
s e v e re VOD than did patients with lymphoma or myeloma.
As noted in Table 4, only one patient with breast cancer had
s e v e re VOD. Although the re l a p s e / remission status at the
time of transplant was only marginally related, the pre s e n c e
of tumor in the liver on an imaging test was significantly
related to moderate and severe VOD. Ta rgeting busulfan lev-
els did not appear to be protective: 30 patients had busulfan
levels targeted, of whom 29 were evaluable in the univariate
analysis of risk factors for moderate and severe VOD. Of
those 29 patients, 17 had their busulfan dosing adjusted
a c c o rding to our protocol (four of 17 developed VOD,
including one severe) and 12 did not have dose adjustments
because their steady-state busulfan concentrations were
a l ready in the target range (seven of 12 developed VOD,
none severe). In the univariate analysis, the practice of targ e t-
ing busulfan levels was not associated with an increased or
d e c reased risk of developing moderate to severe VOD (OR
0.873, confidence interval 0.312–2.440). Nor was there an
a p p a rent relationship between any of the following and mod-
erate or severe VOD (data not shown): age; body weight at
transplant; time span from diagnosis of malignancy to trans-
plant; total number of cycles of chemotherapy before the start
of the harvest regimen for PBSC; adjuvant radiation therapy
at the time of initial patient treatment; or pretransplant seru m
albumin, bilirubin, or alkaline phosphatase levels. The time
f rom PBSC mobilization to transplant was shortest among
patients with severe VOD after transplant (median 44 days
c o m p a red with 61 days for moderate VOD, 67 days for mild
VOD, and 52 days for no VOD), but there was a larg e
amount of variability in these data.
Multivariate model. P redictors of the development of
moderate or severe VOD were diagnosis of lymphoma or
myeloma, tumor involvement in the liver at the time of
transplant, fever in the month before transplant, and radia-
tion therapy given at any time before the start of the trans-
plant process (Table 5). Once these variables were included
in a logistic re g ression model, no others significantly
i m p roved the model. 
DISCUSSION
The incidence of VOD in this series of patients re c e i v i n g
conditioning therapy with busulfan, melphalan, and thiotepa
was 28%, or about half the incidence we re p o rted after high-
dose cytoreductive regimens with cyclophosphamide and
TBI; busulfan and cyclophosphamide; or BCNU, cyclophos-
phamide, and etoposide [1]. Furt h e r, the incidence of severe
VOD in this series was 4%, compared with 15% after the
other high-dose regimens. When only recipients of autolo-
gous hematopoietic grafts are considered, the frequency of
s e v e re VOD was higher in our historical experience [1] than
in the current series (19 vs. 4%). Thus, the rationale for use
of the Bu/Mel/TT regimen seems to have been borne out,
since an encouraging tumor response rate [23,24] and a low
f requency of severe liver toxicity are observed. The low inci-
dence of severe VOD in this series is remarkable, part i c u l a r l y
among patients with breast cancer, among whom only one
patient developed severe VOD.
The lower incidence of VOD and severe VOD with
Bu/Mel/TT may be because the Bu/Mel/TT regimen contains
no cyclophosphamide, now suspected on the basis of in vitro
studies to be the most important hepatic toxin among drugs in
conditioning regimens [10,28–30]. Development of VOD is
likely related not only to toxicity of an individual drug such as
cyclophosphamide but also to certain combinations and to t h e
sequence of drug delivery. Recent clinical studies of the busul-
fan/cyclophosphamide regimen have noted that 1) steady-
state concentrations of busulfan do not correlate well with the
d e v e lopment of VOD [31,32], despite earlier suggestions in
the literature [5,7,33,34]; 2) busulfan influences the metabo-
lism of cyclophosphamide [35]; 3) the risk of VOD varies
with the dose of cyclophosphamide [36]; and 4) exposure to
the metabolites of cyclophophosphamide, as measured by the
a rea under the curve (AUC) for 4-hydro x y c y c l o p h o s p h a m i d e ,
c o rrelates with the development of VOD [35]. Recent in vitro
data show that sinusoidal endothelial cells of the liver are
highly sensitive to the toxic metabolites of cyclophosphamide
and that these metabolites are generated within adjacent hepa-
tocytes [10]. Thus, both clinical and in vitro data point to
high-dose cyclophosphamide as being inherently more toxic
than some other agents to endothelial cells within the liver and
to hepatocytes in zone 3 of the liver acinus. 
Table 3. Mortality to day 100 posttransplant according to the classification of liver disease posttransplant and mortality to day 100
No. of patients Case fatality rate Median day of death 
n (%) who died before day 100 (%) before day 100 (%) before day 100 (range)
All patients 253 22/253 (8.7%) — 44 (3 to 91)
No VOD 150 (60%) 2/253 (0.8%) 2/150 (1.3%) 6, 90
VOD
All 70 (28%) 13/253 (5.1%) 13/70 (18.6%) —
Mild 28 (11%) 1 (0.3%) 1/28 (3.6%) 91 
Moderate 31 (12%) 3 (1.2%) 3/31 (9.7%) 49, 64, 85 
Severe 11 (4%) 9 (3.6%) 9/11 (81.8%) 45 (16 to 60) 
Liver disease of uncertain etiology
All 33 (13%) 7/253 (2.8%) 7/33 (21.2%) 32 (3 to 77)
Sepsis syndrome 18 7 (100%) 7/18 (38.9%) —
Mild hyperbilirubinemia or weight gain 13 — — —
Cardiac failure 1 — — —
GVHD 1 — — —
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This is not to say that busulfan is not a hepatotoxic
drug. Indeed, the current study and clinical studies of busul-
fan/cyclophosphamide regimens suggest that at high busul-
fan doses there is liver toxicity from busulfan [1,7]. In vitro
studies, however, show that effects of busulfan on hepato-
cytes and sinusoidal endothelial cells are complex, and that
the major effects of busulfan are in reducing intracellular
glutathione content and inducing oxidative stress [37]. The
dose of busulfan in the Bu/Mel/TT regimen (12 mg/kg) is
less than that usually used in busulfan/cyclophosphamide
regimens (16 mg/kg), another reason to suggest that busul-
fan is not the major liver toxin in the Bu/Mel/TT regimen.
Melphalan (L-phenylalanine mustard) is metabolized by
hydrolysis and dechlorination in cytochrome P450 and glu-
tathione enzyme systems in the liver [38]. When used alone
in doses of 140 mg/m2 intravenously for the treatment of
myeloma, melphalan caused transient elevations of seru m
AST in 39% and of bilirubin in 25% of 102 patients [39].
Table 4. Univariate analysis of risk factors for moderate and severe VOD among 220 patients who received busulfan/melphalan/thiotepa conditioning therapy  
Comparison of (no VOD + mild VOD)
VOD vs. (moderate + severe VOD)
Risk factors n None Mild Moderate Severe OR 95% CI p value
Sex
Female 164 117 20 20 7 — — —
Male 56 33 8 11 4 1.870 0.909–3.846 0.0889
Radiation therapy before transplant
No 143 111 14 12 6 — — —
Yes 77 39 14 19 5 3.086 1.549–6.150 0.0014
Hormonal manipulation before transplant
None 167 117 21 22 7 — — —
Estrogen/progestin 21 11 2 5 3 2.950 1.121–7.760 0.0284
Anti-estrogen 32 22 5 4 1 0.888 0.315–2.498 0.8213
Mobilization regimen for PBSC harvest
No cyclophosphamide 15 10 1 1 3 — — —
Cyclophosphamide 198 136 26 29 7 0.589 0.216–1.609 0.3020
Mobilization regimen for PBSC harvest
No G-CSF 167 108 23 26 10 — — —
G-CSF 46 38 4 4 0 0.343 0.116–1.018 0.0539
Mobilization regimen for PBSC harvest
Not cyclosphosphamide/taxol 156 104 18 24 10 — — —
Cyclosphosphamide/taxol regimen 57 42 9 6 0 0.418 0.166–1.053 0.0643
Change of body weight from day of PBSC –0.4 0.6 –0.5 –0.8 — — 0.0372
storage to start of conditioning therapy (kg) (–9.5 to (–12 to (–8.4 to (–7.8 to 
36.5) 20.7) 3.2) 1.4)
Days from mobilization of PBSC to transplant 52 67 61 44 — — 0.8141
(14–298) (14–965) (0–659) (35–72)
Fever during the month before transplant
No 181 134 21 19 7 — — —
Yes 39 16 7 12 4 4.174 1.950–8.936 0.0002
Serum AST before the start
of conditioning therapy 24 23 26 26 1.00 0.984–1.023 0.766
(9–163) (14–98) (13–59) (18–49)
Diagnosis*
Breast cancer 111 85 13 12 1 — — —
Lymphoma or myeloma 60 35 6 12 7 3.410 1.544–7.534 0.0024 
All other malignancies 49 30 9 7 3 1.933 0.783–4.774 0.1531
Relapse/remission status at transplant
Remission 80 65 6 7 2 — — —
Refractory or relapse 140 85 22 24 9 2.410 1.088–5.341 0.0302
Tumor in the liver at transplant
(by imaging test)
No 181 132 22 21 6 — — —
Yes 39 18 6 10 5 3.588 1.672–7.700 0.0010
Targeted busulfan level
No 191 132 22 27 10 — — —
Yes 29 18 6 4 1 0.873 0.312–2.440 0.7953
*Two patients had myeloma and myelodysplastic syndrome.
Continuous data are presented as the median and range. Note that 33 patients categorized as having liver disease of uncertain etiology are excluded from this
analysis. CI, confidence interval.
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Intravenous melphalan at 140–240 mg/m2 was given to 79
women with breast cancer, ovarian cancer, or hematologic
malignancy, with no report of liver toxicity [40–42]. When
tandem courses of melphalan at intravenous doses of
140 mg/m2 were given within 3 months of one another to
35 patients with myeloma, one case of fatal VOD re s u l t e d
[43]. When melphalan at doses of 80–140 mg/m2 was fol-
lowed by BCNU and etoposide or cyclophosphamide and
thiotepa, little liver toxicity resulted [44,45]. Thus it seems
unlikely that that melphalan in the doses used in the
Bu/Mel/TT regimen should cause serious liver toxicity.
H o w e v e r, a 10-fold variation in the pharmacokinetics of
intravenous melphalan has been noted [46,47], suggesting
that an individual’s metabolism of the drug may be impor-
tant in toxicity. Furt h e r, the toxicity of melphalan in the
liver may well be enhanced when melphalan is administered
after busulfan, since glutathione depletion alters the clear-
ance of melphalan and glutathione-depleted cells are more
sensitive to the effects of melphalan [38,48]. Indeed, four of
60 patients who received 16 mg/kg busulfan followed by
140 m g / m2 melphalan developed mild to moderate VOD
[20,21]. Adding 135 mg/m2 melphalan to a regimen of
16 mg/kg busulfan and 120 mg/kg cyclophosphamide led to
an unacceptably high prevalence of severe VOD [22].
Thiotepa (N,N9,N0-triethylenethiophosphoramide) is
metabolized by oxidative desulfuration by a P450 mono-oxy-
genase in the liver [49,50]. The major characterized metabo-
lite is TEPA (N,N9,N0-triethylenephosphoramide), which is
markedly less cytotoxic than the parent molecule. Liver and
other organ toxicity correlates with the TEPA peak and the
combined AUC of thiotepa and TEPA [51]. The clearance
half-life for thiotepa decreases with increasing thiotepa dose
[52]. Before the advent of hematopoietic cell transplantation,
the maximally tolerated dose of thiotepa was ,75 mg/m2, a
dose that produces no overt liver toxicity [53,54]. With stem
cell rescue, 10-fold higher doses can be tolerated. In a study o f
intravenous thiotepa as a single agent at doses .800 m g / m2,
fatal VOD developed in one of 14 patients; gastro i n t e s t i n a l
n e c rosis and central nervous system complications were
dose-limiting [55]. There is considerably more experience
with high-dose thiotepa as part of a multiagent conditioning
regimen in the setting of hematopoietic cell transplantation,
but attribution of the cause of hepatic toxicity to individual
agents in these regimens is difficult. For example, a re v i e w
of six studies encompassing 288 patients treated with
6 g / m2 cyclophosphamide, 500 mg/m2 thiotepa, and
8 0 0 – 1 6 0 0 m g / m2 carboplatin found 42 patients labeled as
having liver toxicity, including three with fatal VOD [11–16].
T h ree studies of 450–750 mg/m2 thiotepa, 10–12 mg/kg
busulfan, and 120–150 mg/kg cyclophosphamide in the
t reatment of 197 patients found 50 cases of hepatic toxicity,
including five with fatal VOD [17–19]. It seems likely that
the thiotepa of the Bu/Mel/TT regimen is a contributor to
the VOD seen in this series.
Because all patients in this study received similar doses of
B u / M e l / T T, the risk factor analysis focused on patient vari-
ables that made development of moderate or severe VOD
m o re likely. Having a diagnosis of lymphoma or myeloma
placed patients at higher risk (OR 2.65 compared with
patients with breast cancer, in the multivariate model). Tu m o r
in the liver at the time of transplant, a recent febrile illness
b e f o re transplant, and prior radiation therapy were also risk
factors for moderate or severe VOD. The common theme
linking these variables is probably abnormalities of sinusoidal
endothelial cells in the liver, since these cells are known to be
a l t e red by infla m m a t o ry cytokines and irradiation. 
The clinical presentation of VOD after Bu/Mel/TT is
different from that seen after busulfan/cyclophosphamide or
cyclophosphamide/TBI. For example, the onset of jaundice
is later by 1–2 weeks, and some patients had an even later
onset of signs and symptoms. Patients whose onset of VOD
was later did not appear to have a worse outcome, but a clin-
ical presentation of weight gain and ascites after day 20 was
d i s c o n c e rting to patients and their physicians. In addition,
some patients had two peaks of weight gain and jaundice;
this appeared to be an adverse prognostic sign. The progno-
sis of VOD that presents during or immediately after the
conditioning regimen is likely determined by the extent of
cellular injury in zone 3 of the liver acinus as a result of
d i rect toxicity of cytotoxic drugs and their metabolites
[1,10,56]. A mathematical model has been developed that
p redicts prognosis in VOD that develops after several
cyclophosphamide-containing regimens [56], but because
the pace of disease is different after Bu/Mel/TT, this model
cannot be used for VOD that follows this regimen. It is also
m o re difficult to explain the pathogenesis of severe VOD
whose presentation is delayed several weeks after condition-
ing therapy. A likely hypothesis is that one of the secondary
pathophysiologic events of VOD is operative after Bu/
Mel/TT conditioning. These secondary events include
m i c ro t h romboses in the walls of terminal hepatic venules,
deposition of collagen in sinusoidal spaces, and intrahepatic
vasoconstriction mediated by endothelin-1, for example
[3,4,57]. These phenomena remain unexplored in patients
receiving the Bu/Mel/TT regimen. There were no
responses to thrombolytic therapy among five patients with
s e v e re VOD, perhaps because micro t h romboses are not as
p rominent late in the course of VOD as earlier [3]. VOD
was highly correlated with organ failure, a reprise of what
was seen in other series of patients with VOD, following
other conditioning regimens [1,58-61]. 
In summary, patients at highest risk for moderate or
s e v e re VOD were those with lymphoma or myeloma, a
recent febrile illness, hepatic metastases, and a history of
thoracic or abdominal radiation therapy. The onset of jaun-
dice was significantly later than that seen after busulfan/
cyclophosphamide or cyclophosphamide/TBI re g i m e n s .
Table 5. Results of a multivariate regression model for moderate/severe
VOD
Covariables OR 95% CI p value
Breast cancer 1.0 — —
Lymphoma or myeloma 2.65 1.09–6.41 0.031 
All other malignancies 1.77 0.67–4.73 0.253
Tumor in the liver at transplant 3.95 1.65–9.22 0.002
Fever during the month
before transplant 3.32 1.45–7.60 0.005
Radiation therapy before transplant 2.70 1.25–5.83 0.011
CI, confidence interval.
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Patients with severe VOD could be recognized by the
height of their total serum bilirubin, the amount of weight
gained, the development of fever and organ failure, and by a
second peak of weight gain and jaundice. The etiology of
VOD that follows Bu/Mel/TT therapy may differ in some
ways from that caused by other regimens, and different pre-
vention and treatment strategies may be needed. These data
also have implications for the composition of regimens of
high-dose cytoreductive therapy for hematopoietic cell
transplantation, specifically the question of whether other
alkylating agents should be substituted for cyclophos-
phamide in busulfan/cyclophosphamide and cyclophos-
phamide/TBI regimens, where veno-occlusive disease of the
liver is dose-limiting. If cyclophosphamide, by virtue of its
unique hepatic metabolism, is more liver toxic than equally
e ffective, alternative alkylating agents, then noncyclophos-
phamide-containing regimens should be explored.
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